AIP
MLYS icon

Ameritas Investment Partners’s Mineralys Therapeutics MLYS Stock Holding History

Ameritas Investment Partners’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$103K Hold
3,798
– – ﹤0.01% 1683
2025
Q4 		$138K Buy
3,798
+529
+16% +$21.2K ﹤0.01% 1503
2025
Q3 		$124K Sell
3,269
-726
-18% -$15.7K ﹤0.01% 1551
2025
Q2 		$54.1K Buy
3,995
+1,197
+43% +$17.3K ﹤0.01% 2134
2025
Q1 		$44.4K Hold
2,798
– – ﹤0.01% 2169
2024
Q4 		$34.4K Hold
2,798
– – ﹤0.01% 2397
2024
Q3 		$33.9K Hold
2,798
– – ﹤0.01% 2404
2024
Q2 		$32.7K Buy
2,798
+926
+49% +$11.7K ﹤0.01% 2368
2024
Q1 		$24.2K Buy
1,872
+900
+93% +$11.1K ﹤0.01% 2488
2023
Q4 		$8.36K Hold
972
– – ﹤0.01% 2888
2023
Q3 		$9.24K Hold
972
– – ﹤0.01% 2862
2023
Q2 		$16.6K Hold
972
– – ﹤0.01% 2657
2023
Q1 		$15.2K Buy
+972
New +$16.4K ﹤0.01% 2557

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Ameritas Investment Partners's MLYS Position: Q1 2026 in Review

Ameritas Investment Partners held its Mineralys Therapeutics (MLYS) position steady in Q1 2026 at 3,798 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #1683.

Ameritas Investment Partners first reported a position in MLYS in Q1 2023 and has held it in 13 quarters since. The position peaked at $138K in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Ameritas Investment Partners held 3,798 shares of Mineralys Therapeutics worth $103K as of Q1 2026.
  • Ameritas Investment Partners left its Mineralys Therapeutics share count unchanged in Q1 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #1683 holding.
  • Ameritas Investment Partners first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Ameritas Investment Partners's Mineralys Therapeutics position peaked at $138K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.